What is Personalised, Precision or Stratified
Medicine?
“an innovative approach to tailoring disease prevention and treatment that takes into account differences in people's genes, environments, and lifestyles” - FDA
“a move away from a one size fits all approach to … target therapies to achieve the best outcomes in the management of a patient” - NHS
“medical decisions, practices, interventions and/or products … tailored to the individual patient” - Wikipedia
Physiomics is Uniquely Positioned to Support
the Personalised Treatment of Cancer
Physiomics is working on a number of projects focused on supporting the personalised treatment of cancer. We believe we have a unique combination of capabilities that support our work in this field.
Knowledge of Cancer
Accessing and Curating Data
Population PK/PD Modelling
AI Machine Learning
Discover Physiomics’ Innovative Tool for the Personalised Treatment of Cancer
For its first personalised oncology tool, Physiomics has focused on developing a tool for the personalization of docetaxel dosing in late stage prostate cancer.
If it were to be approved by regulatory authorities, the personalised dosing tool could potentially achieve the following benefits without significantly disrupting the current clinical treatment pathway:
Improve Patient Outcomes
Substantially reduce the occurrence of both under-dosing and over-dosing, leading to improved patient outcomes
Reduce Costs
Reduce costs associated with toxicity-related interventions and drug waste
Minimise Subsequent Expensive Treatments
It can also help postpone the need for subsequent expensive lines of treatment.
Personalised Dosing Tool Overview
Prostate cancer annual incidence 50k in UK, 170k in US
10-20% present with late stage metastatic disease (5 yrsurvival <30%)
Late stage disease typically treated with docetaxel (3 weekly cycles until progression)
Effective ‘underdosing’ and ‘overdosing’ of docetaxel common due to inter-patient variability
Potentially leads to either lack of efficacy or increased toxicity
Wastes healthcare resources and increases costs
We have developed a tool to help physicians understand the effect of the drug in specific patients and enable them to see the possible effect of changing dose
Current personalised-dosing tools typically require costly additional assays and do not provide insight into toxicity or efficacy.
Personalised Dosing Tool Development
Data Identification
Identified public domain data on treatment of prostate cancer using docetaxel for 400+ patients from the comparator arm of a clinical trial
AI & Machine Learning
Applied AI techniques such as neural networks and other machine learning approaches to identify key factors linking dose, toxicity and efficacy
Web-Based Tool
Developed a web-based tool that could, if approved, form the basis of a decision support system for clinicians treating patients with prostate cancer to help reduce cost of toxicity and improve outcomes for patients.
Interested in collaborating with us?
We’ll arrange a brief consultation for you with a specialist in our team.